Aldose reductase inhibitor fidarestat attenuates leukocyte-endothelial interactions in experimental diabetic rat retina in vivo

Current Eye Research

Volumn 35, Issue 2, 2010, Pages 146-154

  Hattori, Tomoaki ^a   Matsubara, Akihisa ^a   Taniguchi, Kaori ^a   Ogura, Yuichiro ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Aldose reductase inhibitor; Diabetic rat retina; Fidarestat; Intercellular adhesion molecule 1; Leukocyte

Indexed keywords

ACRIDINE ORANGE; FIDARESTAT; FRUCTOSE; INTERCELLULAR ADHESION MOLECULE 1; MESSENGER RNA; SORBITOL; STREPTOZOCIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN 164;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INTERACTION; CONTROLLED STUDY; DIABETIC RETINOPATHY; DRUG EFFECT; DRUG MEGADOSE; ENDOTHELIUM CELL; EXPERIMENTAL RAT; FLUOROGRAPHY; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LEUKOCYTE; LEUKOCYTE COUNT; LOW DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RETINA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STREPTOZOCIN DIABETES; TREATMENT DURATION;

ACRIDINE ORANGE; ADMINISTRATION, ORAL; ALDEHYDE REDUCTASE; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; ENDOTHELIUM, VASCULAR; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; FLUORESCENT DYES; FLUOROPHOTOMETRY; FRUCTOSE; IMIDAZOLIDINES; INTERCELLULAR ADHESION MOLECULE-1; LEUKOCYTES; MALE; MICROSCOPY, FLUORESCENCE; RATS; RATS, LONG-EVANS; RETINAL VESSELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SORBITOL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 76749085691     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713680903447918     Document Type: Article

References (57)

1. Gabbay KH. The sorbitol pathway and the complications of diabetes. N Engl J Med 1973;288:831-836.
2. Lorenzi M. The polyol pathway as a mechanism for diabetic retinopathy: Attractive, elusive, and resilient. Exp Diabetes Res 2007;2007:61038.
3. A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Sorbinil Retinopathy Trial Research Group. Arch Ophthalmol 1990;108:1234-1244.
4. Van Zandt MC, Sibley EO, McCann EE, et al. Design and synthesis of highly potent and selective (2-arylcarbamoylphenoxy)- acetic acid inhibitors of aldose reductase for treatment of chronic diabetic complications. Bioorg Med Chem 2004;12:5661-5675.
5. Fong DS, Aiello LP, Ferris FL 3rd, et al. Diabetic retinopathy. Diabetes Care 2004;27:2540-2553.
6. Obrosova IG, Minchenko AG, Vasupuram R, et al. Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats. Diabetes 2003;52: 864-871.
7. Aiello LP. Vascular endothelial growth factor and the eye: Biochemical mechanisms of action and implications for novel therapies. Ophthalmic Res 1997;29:354-362.
8. Kato N, Yashima S, Suzuki T, et al. Long-term treatment with fidarestat suppresses the development of diabetic retinopathy in STZ-induced diabetic rats. J Diabetes Complications 2003;17:374-379.
9. Yamashiro K, Kiryu J, Tsujikawa A, et al. Suppressive effects of selectin inhibitor SKK-60060 on the leucocyte infiltration during endotoxin induced uveitis. Br J Ophthalmol 2003;87:476-480.
10. Cheung AK, Lo AC, So KF, et al. Gene deletion and pharmacological inhibition of aldose reductase protect against retinal ischemic injury. Exp Eye Res 2007;85: 608-616.
11. Schroder S, Palinski W, Schmid-Schonbein GW. Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy. Am J Pathol 1991;139:81-100.
12. Miyamoto K, Hiroshiba N, Tsujikawa A, et al. In vivo demonstration of increased leukocyte entrapment in retinal microcirculation of diabetic rats. Invest Ophthalmol Vis Sci 1998;39:2190-2194.
13. Miyamoto K, Khosrof S, Bursell SE, et al. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci U S A 1999;96:10836-10841.
14. Matsubara A, Tomida K, Matsuda Y, et al. Protective effects of selectin ligands/inhibitor (SKK-60060) against retinal ischemia-reperfusion injury. Exp Eye Res 2000;71: 283-293.
15. Miyaki K, Matsubara A, Nishiwaki A, et al. Pitavastatin attenuates leukocyte-endothelial interactions induced by ischemia-reperfusion injury in the rat retina. Curr Eye Res 2009;34:10-17.
16. Mizuno D, Matsubara A, Ogura Y. Effect of posterior sub-tenon administration of triamcinolone acetonide on leukocyte dynamics in rat retinal microcirculation after panretinal photocoagulation. Invest Ophthalmol Vis Sci 2008;49:2127-2133.
17. Tamai K, Matsubara A, Tomida K, et al. Lipid hydroperoxide stimulates leukocyte-endothelium interaction in the retinal microcirculation. Exp Eye Res 2002;75:69-75.
18. Tomida K, Tamai K, Matsuda Y, et al. Hypercholesterolemia induces leukocyte entrapment in the retinal microcirculation of rats. Curr Eye Res 2001;23:38-43.
19. Guerrant GO, Moss CW. Determination of monosaccharides as aldononitrile, o-methyloxime, alditol, and cyclitol acetate derivatives by gas chromatography. Anal Chem 1984;56:633-638.
20. Kimura H, Kiryu J, Nishiwaki H, et al. A new fluorescent imaging procedure in vivo for evaluation of the retinal microcirculation in rats. Curr Eye Res 1995;14:223-228.
21. Nishiwaki H, Ogura Y, Kimura H, et al. Quantitative evaluation of leukocyte dynamics in retinal microcirculation. Invest Ophthalmol Vis Sci 1995;36:123-130.
22. Nishiwaki H, Ogura Y, Kimura H, et al. Visualization and quantitative analysis of leukocyte dynamics in retinal microcirculation of rats. Invest Ophthalmol Vis Sci 1996;37:1341-1347. (Pubitemid 26177310)
23. Nakazawa T, Nakano I, Sato M, et al. Comparative expression profiles of Trk receptors and Shc-related phosphotyrosine adapters during retinal development: Potential roles of N-Shc/ShcC in brain-derived neurotrophic factor signal transduction and modulation. J Neurosci Res 2002;68:668-680.
24. Nakazawa T, Tamai M, Mori N. Brain-derived neurotrophic factor prevents axotomized retinal ganglion cell death through MAPK and PI3K signaling pathways. Invest Ophthalmol Vis Sci 2002;43:3319-3326.
25. McLeod DS, Lefer DJ, Merges C, et al. Enhanced expression of intracellular adhesion molecule-1 and P-selectin in the diabetic human retina and choroid. Am J Pathol 1995;147:642-653.
26. Nonaka A, Kiryu J, Tsujikawa A, et al. PKC-beta inhibitor (LY333531) attenuates leukocyte entrapment in retinal microcirculation of diabetic rats. Invest Ophthalmol Vis Sci 2000;41:2702-2706.
27. Wierusz-Wysocka B, Wysocki H, Siekierka H, et al. Evidence of polymorphonuclear neutrophils (PMN) activation in patients with insulin-dependent diabetes mellitus. J Leukoc Biol 1987;42:519-523.
28. Freedman SF, Hatchell DL. Enhanced superoxide radical production by stimulated polymorphonuclear leukocytes in a cat model of diabetes. Exp Eye Res 1992;55:767-773.
29. Linsenmeier RA, Braun RD, McRipley MA, et al. Retinal hypoxia in long-term diabetic cats. Invest Ophthalmol Vis Sci 1998;39:1647-1657.
30. Hirata F, Yoshida M, Ogura Y. High glucose exacerbates neutrophil adhesion to human retinal endothelial cells. Exp Eye Res 2006;82:179-182.
31. Butcher EC. Leukocyte-endothelial cell recognition: Three (or more) steps to specificity and diversity. Cell 1991;67:1033-1036.
32. Lawrence MB, Springer TA. Leukocytes roll on a selectin at physiologic flow rates: Distinction from and prerequisite for adhesion through integrins. Cell 1991;65:859-873.
33. Gonzalez RG, Miglior S, Von Saltza I, et al. 31P NMR studies of the diabetic lens. Magn Reson Med 1988;6:435-444.
34. Szwergold BS, Kappler F, Brown TR. Identification of fructose 3-phosphate in the lens of diabetic rats. Science 1990;247:451-454.
35. Frank RN, Amin R, Kennedy A, et al. An aldose reductase inhibitor and aminoguanidine prevent vascular endothelial growth factor expression in rats with long-term galactosemia. Arch Ophthalmol 1997;115:1036-1047.
36. Neuenschwander H, Takahashi Y, Kador PF. Dose- dependent reduction of retinal vessel changes associated with diabetic retinopathy in galactose-fed dogs by the aldose reductase inhibitor M79175. J Ocul Pharmacol Ther 1997;13:517-528.
37. Kowluru RA, Tang J, Kern TS. Abnormalities of retinal metabolism in diabetes and experimental galactosemia. VII. Effect of long-term administration of antioxidants on the development of retinopathy. Diabetes 2001;50:1938-1942.
38. Xia P, Inoguchi T, Kern TS, et al. Characterization of the mechanism for the chronic activation of diacylglycerol- protein kinase C pathway in diabetes and hypergalactosemia. Diabetes 1994;43:1122-1129.
39. Berkowitz BA, Ito Y, Kern TS, et al. Correction of early subnormal superior hemiretinal DeltaPO(2) predicts therapeutic efficacy in experimental diabetic retinopathy. Invest Ophthalmol Vis Sci 2001;42:2964-2969.
40. Kador PF, Takahashi Y, Wyman M, et al. Diabetes-like proliferative retinal changes in galactose-fed dogs. Arch Ophthalmol 1995;113:352-354.
41. Kern TS, Engerman RL. Comparison of retinal lesions in alloxan-diabetic rats and galactose-fed rats. Curr Eye Res 1994;13:863-867.
42. Robison WG Jr, Jacot JL, Glover JP, et al. Diabetic-like retinopathy: Early and late intervention therapies in galactose- fed rats. Invest Ophthalmol Vis Sci 1998;39:1933-1941.
43. Berthet P, Farine JC, Barras JP. Calcium dobesilate: Pharmacological profile related to its use in diabetic retinopathy. Int J Clin Pract 1999;53:631-636.
44. Vinores SA, Van Niel E, Swerdloff JL, et al. Electron microscopic immunocytochemical evidence for the mechanism of blood-retinal barrier breakdown in galactosemic rats and its association with aldose reductase expression and inhibition. Exp Eye Res 1993;57:723-735. (Pubitemid 24039476)
45. Cruz JW, Oliveira MA, Hohman TC, et al. Influence of tolrestat on the defective leukocyte-endothelial interaction in experimental diabetes. Eur J Pharmacol 2000;391:163-174.
46. Collins T, Read MA, Neish AS, et al. Transcriptional regulation of endothelial cell adhesion molecules: NF- kappa B and cytokine-inducible enhancers. Faseb J 1995;9:899-909.
47. Denk A, Goebeler M, Schmid S, et al. Activation of NFkappa B via the Ikappa B kinase complex is both essential and sufficient for proinflammatory gene expression in primary endothelial cells. J Biol Chem 2001;276:28451-28458.
48. Ledebur HC, Parks TP. Transcriptional regulation of the intercellular adhesion molecule-1 gene by inflammatory cytokines in human endothelial cells. Essential roles of a variant NF-kappa B site and p65 homodimers. J Biol Chem 1995;270:933-943.
49. Lockyer JM, Colladay JS, Alperin-Lea WL, et al. Inhibition of nuclear factor-kappaB-mediated adhesion molecule expression in human endothelial cells. Circ Res 1998;82:314-320.
50. Morley SJ. Signalling through either the p38 or ERK mitogen- activated protein (MAP) kinase pathway is obligatory for phorbol ester and T cell receptor complex (TCR-CD3)- stimulated phosphorylation of initiation factor (eIF) 4E in Jurkat T cells. FEBS Lett 1997;418:327-332.
51. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes 1998;47:859-866.
52. Ishii H, Jirousek MR, Koya D, et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996;272:728-731.
53. Yamagishi S, Uehara K, Otsuki S, et al. Differential influence of increased polyol pathway on protein kinase C expressions between endoneurial and epineurial tissues in diabetic mice. J Neurochem 2003;87:497-507.
54. Ramana KV, Bhatnagar A, Srivastava SK. Inhibition of aldose reductase attenuates TNF-alpha-induced expression of adhesion molecules in endothelial cells. Faseb J 2004;18:1209-1218.
55. Ramana KV, Chandra D, Srivastava S, et al. Aldose reductase mediates mitogenic signaling in vascular smooth muscle cells. J Biol Chem 2002;277:32063-32070.
56. Ramana KV, Friedrich B, Bhatnagar A, et al. Aldose reductase mediates cytotoxic signals of hyperglycemia and TNF-alpha in human lens epithelial cells. Faseb J 2003;17:315-317.
57. Ramana KV, Fadl AA, Tammali R, et al. Aldose reductase mediates the lipopolysaccharide-induced release ofinflammatory mediators in RAW264.7 murine macrophages. J Biol Chem 2006;281:33019-33029.